All Stories

Eisai's abandoned Enhertu challenger set to live on at BlissBio

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. Weeks after Eisai quietly made its choice, its liquid biopsy partner has revealed Bliss Biopharmaceutical plans to progress the program independently.

Mar 21, 2025 - 12:29
 0
Eisai's abandoned Enhertu challenger set to live on at BlissBio
BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. Weeks after Eisai quietly made its choice, its liquid biopsy partner has revealed Bliss Biopharmaceutical plans to progress the program independently.
Read More

Tags:

Previous Article

Alfa Romeo unveils details of innovative Q4 system, the project based on efficiency

Next Article

Alanui co-founders repurchase stake in brand from Farfetch’s New Guards Group

Related Posts

NIH allegedly cancels dozens of grants for vaccine hesitancy research: reports

NIH allegedly cancels dozens of grants for vaccine hesi...

Mar 13, 2025  0

With no buyer for Tryvio, Idorsia claws back $100M from a double-asset deal with Viatris

With no buyer for Tryvio, Idorsia claws back $100M from...

Feb 26, 2025  0

Harbour offshoot pens $395M biobucks deal for preclinical rival to Neurocrine’s Crenessity

Harbour offshoot pens $395M biobucks deal for preclinic...

Feb 26, 2025  0